UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 187

Sortiert nach

Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Journal of clinical oncology, 2001-06, Vol.19 (11), p.2865-2874

2001

Volltextzugriff (PDF)

3D scanning technique for morphological analysis of behind armour blunt trauma

International journal of impact engineering, 2024-10, Vol.192, p.105013, Article 105013

2024

Volltextzugriff (PDF)

Prolonged exposure to IL-1β and IFNγ induces necrosis of L929 tumor cells via a p38MAPK NF-κB NO-dependent mechanism

Oncogene, 2008-06, Vol.27 (27), p.3780-3788

2008

Volltextzugriff (PDF)

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5960-5972

2005

Volltextzugriff (PDF)

Immunogenicity of biopharmaceuticals: Implications of PRCA for anaemia management

Toxicology (Amsterdam), 2007-11, Vol.240 (3), p.150-151

Vercammen, Els

2007

Volltextzugriff (PDF)

Endometriosis and Recurrent Pregnancy Loss

Seminars in reproductive medicine, 2000, Vol.18 (4), p.363-368

2000

Volltextzugriff (PDF)

Ideale kristallen: kristalvormen “volgens het boekje”

Gea, 2020-01

E. Vercammen

2020

Volltextzugriff (PDF)

Hepcidin Levels and Erythropoietin Alfa Resistance In Patients with Chemotherapy Induced Anemia (CIA)

Blood, 2010-11, Vol.116 (21), p.3216-3216

2010

Volltextzugriff (PDF)

A randomized, open-label, multicenter study evaluating thrombovascular events (TVEs) in subjects with cancer receiving chemotherapy and administered epoetin alfa (EPO) once weekly (QW) or three times a week (TIW) for the treatment of anemia

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e19550-e19550

2010

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: Results of a randomized, double-blind, placebo-controlled trial

Critical care medicine, 2006-06, Vol.34 (6), p.1661-1667

2006

Volltextzugriff (PDF)

Prolonged exposure to IL-1[beta] and IFN[gamma] induces necrosis of L929 tumor cells via a p38MAPK/NF-[kappa]B/NO-dependent mechanism

Oncogene, 2008-07, Vol.27 (27), p.3780-3788

2008

Volltextzugriff (PDF)

Prolonged exposure to IL-1b and IFNg induces necrosis of L929 tumor cells via a p38MAPK/NF-B/NO-dependent mechanism

Oncogene, 2008-06, Vol.27 (27), p.3780-3788

2008

Volltextzugriff (PDF)

Prolonged exposure to IL-1β and IFNγ induces necrosis of L929 tumor cells via a p38MAPK/NF-KB/NO-dependent mechanism

Oncogene, 2008, Vol.27 (27), p.3780-3788

2008

Volltextzugriff (PDF)

R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo

Thrombosis and haemostasis, 1989, Vol.61 (1), p.43

1989

Volltextzugriff (PDF)

Analysis of the effect of body weight on the efficacy and safety of epoetin alfa

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.8184-8184

2005

Volltextzugriff (PDF)

Renal anaemia - CKD 1-5

Nephrology, dialysis, transplantation, 2012-05, Vol.27 (suppl 2), p.ii133-ii145

2012

Volltextzugriff (PDF)

Population Pharmacokinetics of Erythropoietin in Critically Ill Subjects

Journal of clinical pharmacology, 2005-02, Vol.45 (2), p.193-202

2005

Volltextzugriff (PDF)

Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial

Transfusion (Philadelphia, Pa.), 2001-07, Vol.41 (7), p.957-963

2001

Volltextzugriff (PDF)

Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin

European heart journal, 1994-05, Vol.15 (5), p.660-664

1994

Volltextzugriff (PDF)

Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy

Hematological oncology, 2003-12, Vol.21 (4), p.169-180

2003

Volltextzugriff (PDF)

Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man

Thrombosis and haemostasis, 1992, Vol.68 (2), p.214

1992

Volltextzugriff (PDF)

Management of anemia in patients receiving chemotherapy

Journal of clinical oncology, 2002-01, Vol.20 (2), p.601-603

2002

Volltextzugriff (PDF)

Tolerance and pharmacokinetics of flunarizine after cardiac arrest

Resuscitation, 1989, Vol.17, p.S111-S119

1989

Volltextzugriff (PDF)

Prolonged exposure to IL-1beta and IFNgamma induces necrosis of L929 tumor cells via a p38MAPK/NF-kappaB/NO-dependent mechanism

Oncogene, 2008-06, Vol.27 (27), p.3780

2008

Volltextzugriff (PDF)

The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication

International angiology, 1993-03, Vol.12 (1), p.59

1993

Volltextzugriff (PDF)

1 – 25 von 187

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(178)
Mit Volltextzugriff
(176)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(137)
Life Sciences & Biomedicine
(111)
Humans
(54)
Animals
(48)
Biological And Medical Sciences
(39)
Male
(37)
Female
(33)
Physical Sciences
(28)
Chemistry
(22)
Medical Sciences
(22)
Fundamental And Applied Biological Sciences. Psychology
(19)
Biochemistry & Molecular Biology
(18)
Middle Aged
(18)
Physics
(18)
Materials Science
(16)
Technology
(16)
Pharmacology. Drug Treatments
(14)
Adult
(13)
Exact Sciences And Technology
(13)
Rats
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

3D scanning technique for morphological analysis of behind armour blunt trauma

Prolonged exposure to IL-1β and IFNγ induces necrosis of L929 tumor cells via a p38MAPK NF-κB NO-dependent mechanism

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

Immunogenicity of biopharmaceuticals: Implications of PRCA for anaemia management

Endometriosis and Recurrent Pregnancy Loss

Ideale kristallen: kristalvormen “volgens het boekje”

Hepcidin Levels and Erythropoietin Alfa Resistance In Patients with Chemotherapy Induced Anemia (CIA)

A randomized, open-label, multicenter study evaluating thrombovascular events (TVEs) in subjects with cancer receiving chemotherapy and administered epoetin alfa (EPO) once weekly (QW) or three times a week (TIW) for the treatment of anemia

Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: Results of a randomized, double-blind, placebo-controlled trial

Prolonged exposure to IL-1[beta] and IFN[gamma] induces necrosis of L929 tumor cells via a p38MAPK/NF-[kappa]B/NO-dependent mechanism

Prolonged exposure to IL-1b and IFNg induces necrosis of L929 tumor cells via a p38MAPK/NF-B/NO-dependent mechanism

Prolonged exposure to IL-1β and IFNγ induces necrosis of L929 tumor cells via a p38MAPK/NF-KB/NO-dependent mechanism

R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo

Analysis of the effect of body weight on the efficacy and safety of epoetin alfa

Renal anaemia - CKD 1-5

Population Pharmacokinetics of Erythropoietin in Critically Ill Subjects

Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial

Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin

Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy

Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man

Management of anemia in patients receiving chemotherapy

Tolerance and pharmacokinetics of flunarizine after cardiac arrest

Prolonged exposure to IL-1beta and IFNgamma induces necrosis of L929 tumor cells via a p38MAPK/NF-kappaB/NO-dependent mechanism

The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication

Suchergebnisse filtern